Chimeric antibody market seen topping $10 billion by 2030

The Business Research Company says the global chimeric antibody market will cross $10 billion in 2030, driven by demand for targeted cancer immunotherapies and biologic treatments. North America and the U.S. are expected to lead the market, while intravenous products remain the largest segment.

Why it matters: - Chimeric antibodies are moving deeper into oncology and immunology care as demand rises for targeted biologic therapies. - The forecast points to continued investment in antibody development, manufacturing, and infusion infrastructure through 2030. - The market’s growth also signals expanding commercial opportunity inside the much larger oncology drugs and pharmaceuticals sectors.

What happened: - The Business Research Company projected the global chimeric antibody market will surpass $10 billion in 2030. - The report estimated the market at about 2% of the oncology drugs market, which is expected to reach $441 billion by 2030. - The report said the market will represent nearly 0.4% of the global pharmaceuticals industry, projected at $2.496 trillion by 2030. - The company published the forecast in its report, "Chimeric Antibody Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report said the market is expected to grow at a 6% CAGR through 2030. - North America is projected to be the largest regional market in 2030 at $4.3 billion. - The U.S. is projected to be the largest country market in 2030 at $3.9 billion. - Intravenous products are expected to be the largest type segment in 2030, accounting for 89% of the market, or about $9 billion. - The source also broke the market down by antibody type, manufacturing process, application and end user.

The details: - North America is expected to grow from $3.3 billion in 2025 to $4.3 billion in 2030, at a 5% CAGR. - Growth in North America is tied to biologics adoption in oncology and immunology, a strong base of biopharma innovators and contract manufacturers, more clinical research, higher healthcare spending and reimbursement support. - The U.S. market is expected to rise from $3.0 billion in 2025 to $3.9 billion in 2030, also at a 5% CAGR. - U.S. growth is linked to more monoclonal antibody approvals, greater investment in precision medicine and targeted immunotherapies, a strong biotech research base, higher chronic disease prevalence and more collaborations between pharma companies and research institutions. - The market’s type split includes intravenous and subcutaneous products. - The antibody-type split includes immunoglobulin G chimeric antibodies, fragment antigen-binding chimeric antibodies and single-chain variable fragment chimeric antibodies. - The manufacturing-process split includes recombinant DNA technology, hybridoma technology and phage display technology. - The application split includes cancer therapy, autoimmune diseases, infectious diseases and transplant rejection. - The end-user split includes pharmaceutical companies, research institutes and clinics and hospitals. - The intravenous segment is supported by infusion-based biologic therapy use in hospitals and specialty clinics, established dosing protocols, demand for rapid systemic delivery and expanding infusion infrastructure. - The report said the most significant growth opportunities are in intravenous and subcutaneous products, which together could add more than $3 billion by 2030. - The intravenous segment is projected to add $2 billion over the next five years, while the subcutaneous segment is projected to add $1 billion. - The report’s report package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspots infographics and updated graphics and tables.

Between the lines: - The growth case leans heavily on oncology, which remains the clearest commercial anchor for antibody therapeutics. - North America’s lead suggests the market remains concentrated in regions with deep reimbursement coverage, clinical research capacity and biologics manufacturing networks. - The IV segment’s dominance indicates that administration logistics and specialty-care infrastructure still shape how these therapies reach patients. - The report’s use of forecast percentages for demand drivers shows these estimates are modeled assumptions, not observed outcomes.

What's next: - The report expects targeted cancer immunotherapy demand, antibody engineering advances and rising autoimmune and chronic disease prevalence to keep expanding the market through 2030. - The Business Research Company is offering a free sample report and the full market report for more detail. - The company also directs readers to its social channels, including LinkedIn, LinkedIn, Facebook and X.

The bottom line: - Chimeric antibodies are forecast to stay a fast-growing slice of biologics, with North America, the U.S. and IV delivery leading the way to 2030.